Homepage
Author:
STEALTH BIOTHERAPEUTICS INC.
Posted Date:
May 3, 2026
Stealth BioTherapeutics Provides Commercial Launch Update and Pipeline Progress Across Mitochondrial Disease Portfolio
STEALTH BIOTHERAPEUTICS INC.
May 3, 2026
Stealth BioTherapeutics to Present Clinical Data for Bevemipretide Eye Drops at the Association for Research in Vision and Ophthalmology 2026 Annual Meeting
STEALTH BIOTHERAPEUTICS INC.
May 3, 2026
Stealth BioTherapeutics Appoints David A. Brown, Ph.D., as Chief Scientific Officer to Advance the Company’s Pioneering Work in Mitochondrial Medicine
STEALTH BIOTHERAPEUTICS INC.
May 1, 2026
Stealth BioTherapeutics Announces MRC Business Engagement Fund Grant to Advance Mitochondrial Disease Research
STEALTH BIOTHERAPEUTICS INC.
March 23, 2026
